Supriya Lifescience · NSE: SUPRIYA · BSE: 543434
Q3 FY24 results · Oct–Dec 2023
Supriya Lifescience reported revenue from operations of ₹140.07 crore (up 33.2% from Q3 FY23) and net profit of ₹29.79 crore (up 213.0% from Q3 FY23) for Q3 FY24 (Oct–Dec 2023), on a standalone basis.
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 140.07 | 105.14 | +33.2% | 140.09 | −0.0% |
| Other income | 3.06 | 2.56 | +19.5% | 2.47 | +24.2% |
| Total income | 143.14 | 107.70 | +32.9% | 142.56 | +0.4% |
| Profit before tax | 40.10 | 12.64 | +217.1% | 29.78 | +34.7% |
| Net profit for the period | 29.79 | 9.52 | +213.0% | 23.88 | +24.7% |
| EPS, basic (₹) | 3.70 | 1.18 | +213.6% | 2.97 | +24.6% |
| Net margin (%) | 21.3 | 9.1 | 17.0 |
Standalone
- Filed with BSE
- 21 Feb 2024, 12:12 IST
- Board meeting
- 07 Feb 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE